EUCTR2005-004978-25-SE进行中（未招募）不适用
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)
International Committee for Contraception Research of the Population Council0 个研究点目标入组 2,200 人开始时间: 2006年7月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •a. Healthy women, aged 18-<40 years at the enrollment visit who wish to use a combined hormonal contraceptive
- •b. Women not intending to become pregnant before December 31, 2008
- •c. Intact uterus and both ovaries.
- •d. Prior history of regular menstrual cycles that usually occur every 28 ± 7 days when not using hormonal contraception; if postpartum or postabortal, history of regular menstrual cycles of 21-35 days in length and resumption of at least one cycle with a cycle length consistent with her past cycles.
- •e. Sexually active (currently) and willing to discontinue current contraceptive method to participate in the study.
- •f. In the opinion of the investigator, able to comply with the protocol, e.g. live within the clinic catchment area or within a reasonable distance from the clinic.
- •g. Do not meet any of the exclusion criteria.
- •h. Signed informed consent prior to entry into the trial.
- •Amd9-EX: i. Completion of 13 cycles in Protocol 300B immediately prior to entry in the
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a. Known hypersensitivity to estrogens or progestins
- •b. Known hypersensitivity to silicone rubber.
- •c. Known or suspected pregnancy.
- •d. History of infertility of >1.0 year in woman or her male partner.
- •e. History of vasectomy or sterility in male partner; tubal ligation (sterilization) in women.
- •f. Undiagnosed abnormal genital bleeding.
- •g. Undiagnosed vaginal discharge or vaginal lesions or abnormalities.
- •h. History of pelvic inflammatory disease since last pregnancy episode.
- •i. History of toxic shock syndrome.
- •j. In accordance with the Bethesda system of classification: Women with a current abnormal Pap smear suggestive of high-grade pre-cancerous lesion (s), including HGSIL, are excluded;
- •· Women with LGSIL or ASCUS/high-risk HPV positive may participate if further evaluated with colposcopy and biopsy and no evidence of a lesion with a severity > CIN I is present and/or endocervical curettage is negative.
- •· Women with a biopsy finding of CIN I should have follow up for this finding per standard of care; women are excluded it treatment is indicated.
- •In accordance with other Pap class systems:
- •· Women with high grade dysplasia are excluded.
- •· Women with low grade dysplasia or CIN I interpretation on Pap smear may participate if further evaluated with colposcopy and, as needed, biopsy with endocervical curettage.
- •· Women may participate if colposcopy findings are negative provided there is appropriate follow up in accordance with local standards of care;
- •· Women whose colposcopy results indicate need for biopsy may participate as long as biopsy results indicate there is no lesion with a severity > CIN I and endocervical curettage results are negative.
- •k. Cystoceles or rectoceles or other anatomical abnormality that would preclude use of a vaginal ring.
- •l. Women planning to undergo major surgery.
- •m. Smoking in women who are 35 years and over or will be 35 years during the course of the trial; women < 35yrs who smoke 15 cigarettes or more per day must be evaluated by the PI for inclusion based on risk factors that would increase their risk for CVD and thromboembolism, e.g. lipid levels, glucose level, BP, BMI, family history of CVD at a young age.
- •n. Breastfeeding.
- •o. Current or past thrombophlebitis or thromboembolic disorders.
- •p. History of venous thrombosis or embolism in a first-degree relative, <55 years of age suggesting a familial defect in the blood coagulation system, which in the opinion of the PI, suggests use of a hormonal contraceptive could pose a significant risk.
- •q. Cerebrovascular or cardiovascular disease.
- •r. History of retinal vascular lesions, unexplained partial or complete loss of vision.
- •s. Known or suspected carcinoma of the breast.
- •t. Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia.
- •u. Past history of any other carcinoma unless in remission for more than 5 years.
- •v. Current or history of medically diagnosed severe depression, which, in the opinions of the investigator, could be exacerbated by use of a hormonal contraceptive.
- •w. Headaches with focal neurological symptoms.
- •x. Severe constipation.
- •y. History of cholestatic jaundice of pregnancy or jaundice with prior steroid use.
- •z. Benign or malignant liver tumors; active liver disease.
- •aa. Diastolic blood pressure (BP) >85 mm Hg and/or systolic BP >135 mm Hg after 5-10 minutes rest.
- •bb. Known or suspected alcoholism or drug abuse.
- •cc. Abnormal serum chemistry values according to the physician’s judgment.
研究者
相似试验
进行中（未招募）
不适用
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2005-004978-25-HUInternational Committee for Contraception Research of the Population Council2,200
进行中（未招募）
不适用
A multicenter, open-label study on the efficacy, cycle control and safety of a contraceptivevaginal ring delivering a daily dose of 150 µg of Nestorone(R) and 15 µg of ethinyl estradiol (150/15 NES/EE CVR)As the trial is intended to investigate a new contraceptive medicinal product, the study subjects included are not characterized by a specific medical condition.MedDRA version: 8.1Level: PTClassification code 10010808Term: ContraceptionEUCTR2005-004978-25-FIInternational Committee for Contraception Research of the Population Council2,200
进行中（未招募）
不适用
An open label, multi-center study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura ITPEUCTR2004-000537-11-ITZLB BEHRING60
进行中（未招募）
1 期
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)Subjects with known or suspected Coronary Artery Disease (CAD)EUCTR2012-002563-10-GBBayer AG426
进行中（未招募）
1 期
Gadobutrol/Gadavist-enhanced cardiac magnetic resonance imaging (CMRI) to detect Coronary Artery Disease (CAD)EUCTR2012-002563-10-DEBayer HealthCare AG450